Objective:To investigate the expression of histone deacetylase(HDAC) 11 in classical Hodgkin lymphoma (cHL) and its relationship with clinicopathological features and prognosis. Methods:I mmunohistochemistry was used to detect the expression of HDAC11 in tumor tissues from 56 cHL patients and further studied the relationship between the HDAC11 expression and clinicopathological features and prognosis. Results:Among all patients, 14 cases were negative expression of HDAC11, 28 cases weakly positive and 14 cases positive. In 28 cases of nodular sclerosis type, the high expression rate was 21.4%; in a total of 22 cases of mixed cell type, the high expression rate of 27.2%. The relationship between HDAC11 expressions of Hodgkin-Reed-Steinberg (HRS) in cHL tissue and the gender, age, stage, bulky disease and B symptoms were not significantly differences. The HDAC11 expression had a significant correlation to the extranodal infiltration(χ2=8.185, P=0.011). The median progression free survial(PFS) was 140 months(95% CI 90.1-189.9) and overall survival(OS) was 108 months(95% CI 96.0-119.9) in all 56 patients with cHL. Ten years PFS of HDAC 11 negative expression group was 86%, was more than that of HDAC 11 weak positive group(70%) and that of the HDAC11 positive expression group (15%), the difference was statistically significant (Log-rank P=0.013). Ten years OS of HDAC 11 positive expression group was 100%, was more than that of HDAC weak positive group(78%) and that of HDAC 11 negative expression group(45%), the difference was statistically significant. Conclusion:The expression of HDAC11 relates to the presence of the extranodal infiltration in cHL patients, and is not associated with other clinicopathological features. The low expression of HDAC11 is a co mmon phenomenon. The increased expression of HDAC11 is negatively correlated with PFS and OS in patients with cHL.
 ANSELL S M.Hodgkin lymphoma:2016 update on diagnosis,risk-stratification,and management[J].Am J Hematol,2016,91(4):434-442.
 PERRI F,LONGO F,GIULIANO M,et al.Epigenetic control of gene expression:Potential implications for cancer treatment[J].Critical Reviews in Oncology Hematology,2017,111:166-172.
 TERRANOVA-BARBERIO M,THOMAS S,MUNSTER P N.Epigenetic modifiers in immunotherapy:a focus on checkpoint inhibitors[J].Immunotherapy,2016,8(6):705-719.
 ADAMS H,FRITZSCHE F R,DIRNHOFER S,et al.Class I histone deacetylases 1,2 and 3 are highly expressed in classical Hodgkin's lymphoma[J].Expert Opinion on Therapeutic targets,2010,14(6):577-584.
 GLASER S L,CHANG E T,CLARKE C A,et al.Hodgkin lymphoma incidence in ethnic enclaves in California[J].Leukemia & lymphoma,2015,56(12):3270-3280.
 MULLER B M,JANA L,KASAJIMA A,et al.Differential expression of histone deacetylases HDAC1,2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression[J].BMC Cancer,2013,13:215.
 MARQUARD L,GJERDRUM L M,CHRISTENSEN I J,et al.Prognostic significance of the therapeutic targets histone deacetylase 1,2,6 and acetylated histone H4 in cutaneous T-cell lymphoma[J].Histopathology,2008,53(3):267-277.
 KRISHNA S,KUMAR V,SIDDIQI M I.Recent advances in computer-assisted structure-based identification and design of histone deacetylases inhibitors[J].Current Topics in Medicinal Chemistry,2016,16(9):934-947.
 GLOGHINI A,BUGLIO D,KHASKHELY N M,et al.Expression of histone deacetylases in lymphoma:implication for the development of selective inhibitors[J].Br J Haematol,2009,147(4):515-525.
 BUGLIO D,KHASKHELY N M,VOO K S,et al.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma[J].Blood,2014,124(3):464-465.
 MOYAL L,FELDBAUM N,GOLDFEIZ N,et al.The therapeutic potential of AN-7,a novel histone deacetylase inhibitor,for treatment of mycosis fungoides/sezary syndrome alone or with doxorubicin[J].PLoS One,2016,11(1):e0146115.